 |
Articles: Myeloproliferative Dz |
Prior Articles
CBL Exon 8/9 Mutants Activate the FLT3 Pathway and Cluster in Core Binding Factor/11q Deletion Acute Myeloid Leukemia/Myelodysplastic Syndrome Subtypes
Clinical Cancer Research, 04/06/09
Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation
Haematologica, 04/03/09
Free full text
Immune mediated autologous cytotoxicity against hematopoietic precursor cells in patients with myelodysplastic syndrome
Haematologica, 04/03/09
Free full text
Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13
Blood, 04/02/09
Evidence Based Medicine
Oligonucleotide array CGH studies in myeloproliferative neoplasms: Comparison with JAK2V617F mutational status and conventional chromosome analysis
Leukemia Research, 04/01/09 Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.
National Cancer Institute, 03/31/09 Deletion 5q in myelodysplastic syndrome: a paradigm for the study of hemizygous deletions in cancer
Leukemia, 03/31/09 Whole-body MRI versus PET in assessment of multiple myeloma disease activity
American Journal of Roentgenology, 03/24/09 DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma
Annals of Hematology, 03/18/09 Altered naive and memory CD4+ T-cell homeostasis and immunosenescence characterize younger patients with myelodysplastic syndrome
Leukemia, 03/18/09 United Kingdom myeloma forum position statement on the use of lenalidomide in multiple myeloma
International Journal of Laboratory Hematology, 03/16/09 Auer rod-like intracytoplasmic inclusions in multiple myeloma. A case report and review of the literature
International Journal of Laboratory Hematology, 03/16/09 HFE C282Y Mutation as a Genetic Modifier Influencing Disease Susceptibility for Chronic Myeloproliferative Disease
Cancer Epidemiology, Biomarkers & Prevention, 03/13/09 Unfavorable lipoprotein profile in childhood cancer survivors with suprasellar brain tumors - a high Apo B level and increased small dense LDL-cholesterol
Child's Nervous System, 03/12/09 The treatment of multiple myeloma using vincristine, carmustine, melphalan, cyclophosphamide, and prednisone (VBMCP) alternating with high-dose cyclophosphamide and [alpha]2[beta] interferon versus VBMCP
Cancer, 03/12/09 Hematologic Response to Three Alternative Dosing Schedules of Azacitidine in Patients With Myelodysplastic Syndromes
Journal of Clinical Oncology, 03/10/09
Evidence Based Medicine
Second Stem Cell Transplant Not Helpful in Myeloma
National Cancer Institute, 03/03/09 Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy
Thrombosis Research, 02/27/09 Longitudinal analysis and prognostic effect of cancer-testis antigen expression in multiple myeloma
Clinical Cancer Research, 02/26/09 Regulation of the CD56 promoter and its association with proliferation, anti-apoptosis and clinical factors in multiple myeloma
Leukemia and Lymphoma, 02/26/09
|
|
Receive free subspecialty "5-minute updates" via email
|
|
Indexed Journals: Journal of Clinical Oncology, Cancer Research, Annals Oncology
more...
|
188 Available Pages
|
|
